Filing Details
- Accession Number:
- 0000899243-21-011435
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-03-12 20:00:40
- Reporting Period:
- 2021-03-10
- Accepted Time:
- 2021-03-12 20:00:40
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1403752 | Zymeworks Inc. | ZYME | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1729957 | J. Anthony Polverino | C/O Zymeworks Inc. 1385 West 8Th Avenue, Suite 540 Vancouver A1 V6H 3V9 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Shares | Acquisiton | 2021-03-10 | 2,500 | $0.00 | 32,027 | No | 4 | M | Direct | |
| Common Shares | Disposition | 2021-03-10 | 1,048 | $34.95 | 30,979 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Shares | Restricted Stock Unit | Disposition | 2021-03-10 | 2,500 | $0.00 | 2,500 | $0.00 |
| Common Shares | Stock Option (Right to Buy) | Acquisiton | 2021-03-10 | 48,750 | $0.00 | 48,750 | $34.82 |
| Common Shares | Restricted Stock Unit | Acquisiton | 2021-03-10 | 8,125 | $0.00 | 8,125 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 5,000 | No | 4 | M | Direct | ||
| 48,750 | 2031-03-09 | No | 4 | A | Direct | |
| 8,125 | No | 4 | A | Direct |
Footnotes
- Represents common shares issued upon vesting of one third of the restricted stock units ("RSUs") granted on March 10, 2020.
- Represents common shares sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs. Pursuant to the terms of the applicable RSU grant agreement (the "Grant Agreement"), effective on the grant date of the RSUs, the Reporting Person irrevocably adopted a 10b5-1 plan pursuant to which the Reporting Person elected to sell shares to cover tax withholding obligations and other applicable fees in accordance with the terms of the Grant Agreement.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.80 to $35.15, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
- The RSUs were granted on March 10, 2020 and vest in three equal annual instalments beginning on March 10, 2021.
- Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date.
- The RSUs vest in three equal annual installments beginning on March 10, 2022.
Billionaire Hedge Funds
